Muscle-Invasive Bladder Carcinoma Clinical Trials

19 recruiting

Muscle-Invasive Bladder Carcinoma Trials at a Glance

19 actively recruiting trials for muscle-invasive bladder carcinoma are listed on ClinicalTrialsFinder across 6 cities in 9 countries. The largest study group is Phase 2 with 9 trials, with the heaviest enrollment activity in St Louis, New York, and Minneapolis. Lead sponsors running muscle-invasive bladder carcinoma studies include Cairo University, Columbia University, and Alliance for Clinical Trials in Oncology.

Browse muscle-invasive bladder carcinoma trials by phase

Treatments under study

About Muscle-Invasive Bladder Carcinoma Clinical Trials

Looking for clinical trials for Muscle-Invasive Bladder Carcinoma? There are currently 19 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Muscle-Invasive Bladder Carcinoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Muscle-Invasive Bladder Carcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 119 of 19 trials

Recruiting

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Head and Neck CarcinomaMalignant Solid NeoplasmSarcoma+59 more
Alliance for Clinical Trials in Oncology2,000 enrolled745 locationsNCT05334069
Recruiting
Phase 1

Adaptive RADiation Therapy With Concurrent Sacituzumab Govitecan (SG) for Muscle Invasive Bladder Cancer

Muscle-Invasive Bladder CarcinomaLocalized Muscle Invasive Bladder Urothelial Carcinoma
Shilpa Gupta, MD20 enrolled1 locationNCT05833867
Recruiting
Phase 1Phase 2

Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder Cancer

Muscle-Invasive Bladder CarcinomaBladder CancerStage II Bladder Cancer AJCC v8+1 more
University of California, San Francisco47 enrolled1 locationNCT06470282
Recruiting
Not Applicable

Clinical Trial to Evaluate Post-Operative Outcomes of Ureteral Stent vs Ureteral Stent Free Radical Cystectomy

Urothelial CarcinomaMuscle-Invasive Bladder CarcinomaBladder Cancer+3 more
Thomas Jefferson University70 enrolled2 locationsNCT07234968
Recruiting
Phase 2

Bladder Preservation for Patients With Muscle Invasive Bladder Cancer (MIBC) With Variant Histology

Muscle-Invasive Bladder CarcinomaTumor
Leslie Ballas20 enrolled1 locationNCT06417190
Recruiting
Phase 1

Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease

Muscle-Invasive Bladder CarcinomaGastroesophageal Adenocarcinoma
Washington University School of Medicine32 enrolled1 locationNCT06529822
Recruiting
Not Applicable

Supporting Sexual Health in Bladder Cancer Patients: A Sequential Mixed-Methods Intervention Study

Muscle-Invasive Bladder CarcinomaBladder CancerNon-Muscle-Invasive Bladder Cancer (NMIBC)
University of Aarhus30 enrolled1 locationNCT07339761
Recruiting
Not Applicable

Interest of Late Images for the Assessment of Extensions in 18FGD PET-CT of Muscle-Invasive Bladder Cancers

Muscle-Invasive Bladder CarcinomaBladder Cancer
Hopital Foch66 enrolled1 locationNCT06537960
Recruiting
Early Phase 1

Prophylactic Antibiotics in Cystectomy With Diversion

Muscle-Invasive Bladder CarcinomaRadical CystectomyIleal Conduit+1 more
University of Minnesota120 enrolled1 locationNCT06190197
Recruiting
Phase 2

Gemcitabine/Cisplatin Plus Cemiplimab With or Without Fianlimab in Localized Muscle-invasive Bladder Cancer (NeoSTOP-IT)

Muscle-Invasive Bladder CarcinomaBladder Cancer
Columbia University36 enrolled1 locationNCT06571708
Recruiting
Phase 2Phase 3

NEO-BLAST: Neoadjuvant Therapy for Bladder Cancer Followed by Active Surveillance vs Treatment

Muscle-Invasive Bladder Carcinoma
Peter Black688 enrolled1 locationNCT06537154
Recruiting
Phase 2

Surveillance of the Genetic Signature in Circulating Tumor DNA for Guiding Adjuvant Chemotherapy in Urothelial Carcinoma

Muscle-Invasive Bladder CarcinomaMuscle Invasive Bladder Urothelial Carcinoma
Yung NA20 enrolled1 locationNCT06257017
Recruiting
Phase 2Phase 3

Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors

Metastatic Urothelial CarcinomaMuscle-Invasive Bladder Carcinoma
Vasgene Therapeutics, Inc700 enrolled1 locationNCT06493552
Recruiting
Phase 2

Evaluating the Impact of 18F-FDG-PET-CT on Risk Stratification and Treatment Adaptation for Patients with Muscle Invasive Bladder Cancer

Muscle-Invasive Bladder Carcinoma
University Hospital, Ghent156 enrolled1 locationNCT04724928
Recruiting
Phase 1Phase 2

RC48 Combined with Toripalimab As Neoadjuvant Therapy for Cisplatin Ineligible MIBC Patients

Muscle-Invasive Bladder CarcinomaBladder Cancer
Zhujiang Hospital55 enrolled1 locationNCT06341400
Recruiting
Phase 2

Cisplatin, Nab-paclitaxel, Nivolumab With Radiotherapy After Resection of Non-Metastatic Muscle Invasive Bladder Cancer

Muscle-Invasive Bladder Carcinoma
Fondazione Policlinico Universitario Agostino Gemelli IRCCS32 enrolled1 locationNCT05203913
Recruiting
Phase 4

The Nephroprotective Effect of Metformin With Cisplatin in Bladder Cancer

Muscle-Invasive Bladder Carcinoma
Cairo University78 enrolled1 locationNCT06215976
Recruiting

Study on the Quality of Life and Pathological State in Patients Who Underwent Radical Cystectomy

Muscle-Invasive Bladder CarcinomaBladder CancerMuscle Invasive Bladder Urothelial Carcinoma+14 more
IRCCS San Raffaele4,000 enrolled1 locationNCT06170177
Recruiting

Robotic Radical Cystectomy Outcomes

SurgeryMuscle-Invasive Bladder CarcinomaBladder Cancer+2 more
University of Florence500 enrolled1 locationNCT04900558